Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Seeking Alpha

May 24, 2021

Abivax reports strong phase 2 data on ulcerative colitis candidate; shares up 12%

Forbes

May 19, 2021

Promising Pharma Plays For Investors

HCPLive

April 20, 2021

The Potential of ABX464 for Ulcerative Colitis

Scrip

April 6, 2021

Abivax Poised For ‘Transformational’ Q2

BIOTECHFINANCES

April 2, 2021

Biotechs : la science de la résilience

  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn